AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03138668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Injection
Description: All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Study NCT00968175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided celiac plexus neurolysis (CPN)
Description: Initial procedure and rescue procedure if applicable
Study NCT00596011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenon E
Description: Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
Study NCT00596011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo BID
Study NCT02661438 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Ciprofloxacin DPI (BAYQ3939)
Description: Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
Study NCT01588002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: multiple oral doses
Study NCT01588002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: multiple oral doses
Study NCT01588002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: multiple oral doses
Study NCT01588002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: multiple oral doses
Study NCT01588002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: multiple oral doses
Study NCT01588002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: multiple oral doses
Study NCT01479907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotics
Description: 12 gr in 250 cc of water once daily X 15 days
Study NCT01479907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 gr in 250 cc of water once daily X 15 days
Study NCT00215774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
Study NCT01440322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color
Study NCT01440322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens
Description: Silicone hydrogel contact lens
Study NCT03237234 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor Skill Training
Description: Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
Study NCT03237234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Skill Training
Description: Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
Study NCT03237234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
Study NCT04118010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: High-dose vitamin D3 50,000 IU /week for 12 weeks
Study NCT04118010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vitamin D3
Description: Matching to Vitamin D3 placebo capsules for 12 weeks
Study NCT04118010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vitamin D3
Description: Matching to Vitamin D3 placebo capsules for 12 weeks
Study NCT04118010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Chicory-derived prebiotic inulin 12 g/day for 12 weeks
Study NCT04118010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inulin
Description: Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
Study NCT04118010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inulin
Description: Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
Study NCT04659070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental : Ezetimibe / Rosuvastatin + Telmisartan
Description: Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
Study NCT04659070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator1 : Ezetimibe / Rosuvastatin
Description: Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
Study NCT04659070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator2 : Telmisartan
Description: Telmisartan 80mg PO, Once daily for 8 weeks
Study NCT00393055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: 1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
Study NCT00393055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: inactive lozenge
Description: 1g inactive lozenge, dissolved in mouth. Five/day for three years
Study NCT04537806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Administered as IV infusion.
Study NCT04537806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as IV infusion.
Study NCT02548988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Selective Neuromuscular Electrical Stimulation on VMO
Study NCT01703481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 1
Description: Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
Study NCT01703481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 2
Description: Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
Study NCT01703481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 3
Description: Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
Study NCT01703481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 4
Description: Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
Study NCT01361789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib, valdecoxib, parecoxib and dexamethasone
Description: combination of both drugs
Study NCT00525200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluoruracil, Cisplatinum
Description: 5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21
Study NCT00525200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, day 1; 3 cycles; q21
Study NCT01958047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral
Study NCT04004806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hill Rom tracking device
Description: Location tracking devices from Hill Rom company.
Study NCT01670942 — intervention group
Intervention type: OTHER
Intervention: hypobaric chamber
Description: We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
Study NCT00234299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325mg, one tablet orally, six months
Study NCT00234299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 325mg, one tablet orally every day, 6 months
Study NCT02420847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02420847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02420847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT03196622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handgrip test
Description: Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
Study NCT03460132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomas® Anchorage System - DENTAURUM
Description: self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
Study NCT00825513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akreos Toric IOL
Description: Lens implant following cataract surgery
Study NCT00825513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
Description: Lens implant following cataract surgery
Study NCT02879669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Study NCT02879669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/cisplatin (carboplatin)
Study NCT02879669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/cisplatin (carboplatin)
Study NCT02879669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01964118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting group
Description: Intermittent fasting for 12 months
Study NCT01964118 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: usual diet for 6 months and intermittent fasting for other 6 months
Study NCT03394508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK Alutard birch or 5-grasses
Description: Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.
Study NCT03067779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mHealth Tool
Description: The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy.
Study NCT01434823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocturnal coverage
Description: The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage.
Study NCT00622427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: 8 mg tablets every night for 2 weeks
Study NCT00622427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablets for every night for 2 weeks
Study NCT01229475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation with stepwise approach
Description: Stepwise approach for repeat AF ablation
Study NCT01229475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear ablation
Description: Linear ablation for AF ablation
Study NCT02967952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway (SGA) V.S. endotracheal intubation (ETI)
Description: already being described above
Study NCT04214691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Study NCT01045291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Description: Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
Study NCT01045291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Description: Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
Study NCT04135716 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with assistance of Endo.Angel
Description: Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
Study NCT04135716 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Colonoscopy without assistance of Endo.Angel
Description: Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
Study NCT01873482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement to rhythm
Description: Movement to rhythm
Study NCT02703103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual chest compressions
Description: 2 min of Chest compressions without mechanical chest compression system
Study NCT02703103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARM chest compressions
Description: 2 min of Chest compressions with mechanical chest compression system LifeLine ARM
Study NCT01376011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: quercetin/placebo
Description: Quercetin 500mg once per day versus placebo
Study NCT03438435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRH-882260 Heptapeptide
Description: Imaging agent
Study NCT02550964 — intervention group
Intervention type: PROCEDURE
Intervention: Composite Examination
Description: First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
Study NCT02484105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comforting Conversation
Description: Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
Study NCT02484105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Communication
Description: Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
Study NCT02484105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Communication
Description: Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
Study NCT01980849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin, long term
Study NCT01980849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin: short-term
Study NCT03215355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primovist
Description: Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety.
Study NCT04543552 — intervention group
Intervention type: DEVICE
Intervention: Bladder scan
Description: Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
Study NCT03126981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.5 oz of whole, natural almonds
Description: 1.5 oz of whole, natural almonds
Study NCT03126981 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-fat, high refined starches/sugars
Description: Low-fat foods, high in refined starches and added sugars
Study NCT00807781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mammaglobin-A DNA vaccine
Study NCT02206113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing workstation
Study NCT02206113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing workstation
Study NCT03228680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: Single daily subcutaneous administration through pre-filled injection pen
Study NCT03228680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta
Description: Single daily subcutaneous injection in the abdomen
Study NCT03318848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video during simulation
Description: The intervention group simulated the bed bath while watching the video, under the supervision of the tutor